多替阿巴拉米片是什么药？

GlaxoSmithKline (GSK) announced on January 20 that its joint venture ViiV Healthcare1's single-pill compound preparation Suimeikai (chemical name: Dolutegravir) as the core for the treatment of HIV, which is a new generation integrase inhibitor, Trivicavir (chemical name: Dolutegravir), was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. As an innovative single-pill compound preparation with obvious clinical therapeutic advantages, dolutea palamid tablets (TRIUMEQ) can provide great convenience for the treatment of HIV-infected patients. 

Dolutegravir (TRIUMEQ) is the only three-in-one compound drug with dolutegravir (DTG) as the core. It has the characteristics of high efficacy, good tolerance, high resistance barrier, and few drug interactions. Dolutegravir can significantly reduce the medication burden of HIV-infected patients, thereby improving patients' medication compliance and significantly improving their quality of life. Dolutegravir tablets (TRIUMEQ) are compound preparations. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir) 600 mg and lamivudine 300 mg. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Among them, dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). 

For adults and adolescents, the recommended dose of Dolutegra is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. 

Once infected with AIDS, it will lead to a rapid decline in immunity. When immunity declines, it is easy to get sick and other symptoms will appear. When the HIV virus enters the human body, it will not make the human body feel abnormal very quickly, so the disease needs to be treated. There are many hazards. Due to the decline of the body's resistance, various infections will occur, such as herpes zoster, oral mold infection, tuberculosis, enteritis, pneumonia, encephalitis caused by special pathogenic microorganisms, severe infections caused by Candida, Pneumocystis jiroveci and other pathogens. In the later stage, malignant tumors often occur, and long-term consumption occurs, leading to systemic failure and death. The advent of AIDS has helped patients alleviate their pain to a certain extent, delayed the progression of the disease, and brought hope to AIDS patients.